富祥药业
(300497)
| 流通市值：35.25亿 | | | 总市值：43.34亿 |
| 流通股本：4.47亿 | | | 总股本：5.50亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,286,439,179.08 | 855,645,582.63 | 397,918,173.64 | 1,647,263,426.9 |
| 营业收入 | 1,286,439,179.08 | 855,645,582.63 | 397,918,173.64 | 1,647,263,426.9 |
| 二、营业总成本 | 1,364,463,759.45 | 914,724,943.64 | 431,474,684.77 | 1,624,123,494.15 |
| 营业成本 | 1,141,735,318.84 | 772,723,363.89 | 356,203,411.79 | 1,350,160,738.84 |
| 税金及附加 | 11,451,859.74 | 6,680,759.13 | 3,315,143.81 | 15,234,230.77 |
| 销售费用 | 29,177,740.44 | 19,605,122.15 | 8,988,432.14 | 34,212,237.19 |
| 管理费用 | 102,907,678.16 | 68,809,243.66 | 32,622,160.7 | 147,277,948.73 |
| 研发费用 | 63,502,264.13 | 39,639,927.9 | 19,477,717.76 | 77,450,427.53 |
| 财务费用 | 15,688,898.14 | 7,266,526.91 | 10,867,818.57 | -212,088.91 |
| 其中:利息费用 | 31,536,714.11 | 20,771,786.93 | 10,224,924.45 | 41,098,468.23 |
| 其中:利息收入 | 6,802,475.18 | 4,600,492.69 | 2,471,131.06 | 23,294,395.87 |
| 加:公允价值变动收益 | -92,581.63 | -1,926,624.11 | -1,197,264.37 | -79,248,677.2 |
| 加:投资收益 | -4,354,303.21 | -3,015,876.63 | 665,887.43 | -3,681,902.48 |
| 资产处置收益 | -7,089.69 | -7,089.69 | -7,089.69 | 408,354.02 |
| 资产减值损失(新) | -1,852,730.74 | -3,368,677.25 | - | -85,831,385.72 |
| 信用减值损失(新) | -6,204,023.52 | -4,150,207.01 | -755,810.86 | -3,505,437.93 |
| 其他收益 | 4,467,908.74 | 3,659,264.78 | 1,048,401.69 | 14,764,232.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -86,067,400.42 | -67,888,570.92 | -33,802,386.93 | -133,954,884.36 |
| 加:营业外收入 | 768,241.69 | 537,518.81 | 307,002.3 | 558,664.72 |
| 减:营业外支出 | 1,426,076.2 | 551,279.88 | 84,134.26 | 9,311,142.42 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -86,725,234.93 | -67,902,331.99 | -33,579,518.89 | -142,707,362.06 |
| 减:所得税费用 | 6,183,866.58 | 36,429.45 | 11,314.19 | 21,467,179.2 |
| 六、净利润 | -92,909,101.51 | -67,938,761.44 | -33,590,833.08 | -164,174,541.26 |
| 持续经营净利润 | -92,909,101.51 | -67,938,761.44 | -33,590,833.08 | -164,174,541.26 |
| 归属于母公司股东的净利润 | -81,636,876.41 | -59,674,511.28 | -30,146,940.29 | -141,471,326.16 |
| 少数股东损益 | -11,272,225.1 | -8,264,250.16 | -3,443,892.79 | -22,703,215.1 |
| (一)基本每股收益 | -0.15 | -0.11 | -0.06 | -0.26 |
| (二)稀释每股收益 | -0.15 | -0.11 | -0.06 | -0.26 |
| 八、其他综合收益 | - | - | - | 10,787,367.7 |
| 归属于母公司股东的其他综合收益 | - | - | - | 10,787,367.7 |
| 九、综合收益总额 | -92,909,101.51 | -67,938,761.44 | -33,590,833.08 | -153,387,173.56 |
| 归属于母公司股东的综合收益总额 | -81,636,876.41 | -59,674,511.28 | -30,146,940.29 | -130,683,958.46 |
| 归属于少数股东的综合收益总额 | -11,272,225.1 | -8,264,250.16 | -3,443,892.79 | -22,703,215.1 |
| 公告日期 | 2023-10-25 | 2023-08-31 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |